These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31394261)

  • 1. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
    Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
    Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
    Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
    Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
    Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
    J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
    Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
    Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors.
    Su CY; Chen M; Chen LC; Ho YS; Ho HO; Lin SY; Chuang KH; Sheu MT
    Drug Deliv; 2018 Nov; 25(1):1066-1079. PubMed ID: 29718725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
    Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
    Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
    Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
    Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.
    Howard CB; Fletcher N; Houston ZH; Fuchs AV; Boase NR; Simpson JD; Raftery LJ; Ruder T; Jones ML; de Bakker CJ; Mahler SM; Thurecht KJ
    Adv Healthc Mater; 2016 Aug; 5(16):2055-68. PubMed ID: 27283923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
    Lin WW; Cheng YA; Li CC; Ho KW; Chen HJ; Chen IU; Huang BC; Liu HJ; Lu YC; Cheng CM; Huang MY; Lai HW; Cheng TL
    Sci Rep; 2021 Apr; 11(1):7598. PubMed ID: 33828191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
    Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
    J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
    Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
    MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
    Kao CH; Wang JY; Chuang KH; Chuang CH; Cheng TC; Hsieh YC; Tseng YL; Chen BM; Roffler SR; Cheng TL
    Biomaterials; 2014 Dec; 35(37):9930-9940. PubMed ID: 25212525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts: targeted polymer drug conjugates for cancer diagnosis and therapy.
    Khaw BA; Gada KS; Patil V; Panwar R; Mandapati S; Hatefi A; Majewski S; Weisenberger A
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1603-16. PubMed ID: 24643779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies.
    Cui J; Ju Y; Houston ZH; Glass JJ; Fletcher NL; Alcantara S; Dai Q; Howard CB; Mahler SM; Wheatley AK; De Rose R; Brannon PT; Paterson BM; Donnelly PS; Thurecht KJ; Caruso F; Kent SJ
    Adv Healthc Mater; 2019 May; 8(9):e1801607. PubMed ID: 30868751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
    de Goeij BE; Vink T; Ten Napel H; Breij EC; Satijn D; Wubbolts R; Miao D; Parren PW
    Mol Cancer Ther; 2016 Nov; 15(11):2688-2697. PubMed ID: 27559142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects
    Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Bahadori T; Judaki MA; Shiravi F; Zare HA; Haghighat FN; Mobini M; Amiri MM; Shokri F
    Front Immunol; 2020; 11():600883. PubMed ID: 33679691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.